Fadi Haddad: Management of Chronic Myeloid Leukemia During Pregnancy
Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a post on X by Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, adding:
“Check out our latest publication and recommendations on the management of CML during pregnancy.
Our algorithm below summarizes best practices depending on trimester.
- Imatinib and Nilotinib = safest
- Dasatinib and Bosutnib = contraindicated”
Quoting Naveen Pemmaraju‘s post:
“New paper alert
Led by Dr Fadi Haddad.
Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm – Clinical Lymphoma, Myeloma and Leukemia”
Title: Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm
Journal: Clinical Lymphoma, Myeloma and Leukemia
Authors: Fadi G. Haddad, Jennifer Croden, Koji Sasaki, Ghayas C. Issa, Naveen Pemmaraju, Hagop Kantarjian, Elias Jabbour
More posts featuring Fadi Haddad on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023